This is a preview of subscription content, log in via an institution to check access.
References
Agerty HA. Lead poisoning in children. Medical Clinics of North America. 1952;36:1587.
Belknap EL. EDTA in the treatment of lead poisoning. Indust Med & Surg 1952;21:305.
Bessman SP, Ried H, Rubin M. Treatment of lead encephalopathy with calcium disodium versenate. Ann Med Soc DC 1952;21:312.
Chisolm JJ Jr. Chelation therapy in children with subclinical plumbism. Pediat 1974;53:441.
Chisolm JJ Jr. The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediat 1968;73:1.
Clarke NE Sr, Clarke NE Jr, Mosher RE. Treatment of occlusive vascular disease with disodium ethylene diamine tetraacetic acid (EDTA). Amer J Med Sci 1960;732:110.
Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetra-acetic acid. Am J Med Sci 1956;232:654.
Clarke NE Sr. Atherosclerosis, occlusive vascular disease and EDTA. Am J Cardiol 1960;6:233.
Clarke NE, Clarke CN, Mosher RE. The “in vivo” dissolution of metastatic calcium: An approach to atherosclerosis. Am J Med Sci 1955;229:142.
Foreman H. Pharmacology of some useful chelating agents. In Seven MJ, Johnson LA eds. Metal-Binding in Medicine. Philadelphia, JB Lippincott, 1960.
Halstead BW. The Scientific Basis of EDTA Chelation Therapy. Colton, CA, Golden Quill Publishers, Box 1278, Colton, CA 92324, 1979.
Popovici A, Geschecter C, Reinovsky A et al. Experimental control of calcium levels in vivo. Proc Soc Exp Biol Med 1950;74: 415.
Spencer H, Greenberg J, Berger E et al. Studies on the effect of ethylene diamine tetraacetic acid in hypercalcemia. J Lab Clin Med 1956;47: 29.
Seven MJ. Observations on the dosage of intravenous chelating agents. Antibiotic Med 1958;5:251.
Chen IW, Park HM, King LR et al. Radioimmunoassay of parathyroid hormone: peripheral plasma immunoreactive parathyroid hormone response to ethylene diamine tetraacetate. J Nucl Med 1974;15:763.
Jones KH, Fourman P. Edetic-acid test of parathyroid insufficiency. Lancet 1963;2:119.
Wong G. The chemistry of EDTA (a brief treatment). H Harper and G Gordon (Eds.). Reprints of Medical Literature on Chelation Therapy. Amer Acad Med Prev Los Angeles, 1974.
Ghiringhelli L, Respighi E. The tubular reabsorption of phosphorus during the test of parathyroid stimulation by versenate (test of Kaiser &Ponsold). Atti Acad Med Lombarda 1963;18:191.
Ghiringhelli L, Marinoni E, Respighi E. Study of the parathyroid function by means of the Kaiser & Ponsold test in a group of thyroidectomized patients. Minerva Med 1963;54:2829.
Konradi MG. Use of the disodium ethylene diamine tetraacetate for diagnosing latent forms of hypoparathyroidism. Prob Endokrinol (Russ.) 1977;(23)3:46.
Tsang RC, Chen I-W, McEnerg P. Parathyroid function tests with EDTA infusions in infancy and childhood. J Pediatr 1976;88:250.
Rassmussen H, Bordier P. The Physiological and Cellular Basis of Metabolic Bone Disease. Williams and Wilkins, Baltimore, 1974.
Rudolph CJ, McDonagh EW, Wussow, DG. The effect of intravenous ethylene diamine tetraacetic acid (EDTA) upon bone density levels. J Advancement Med 1988;1(2):79.
Spencer H, Vankinscott V, Lewin I et al. Removal of calcium in man by ethylene diamine tetraacetic acid. (EDTA). J Clin Invest 1952;31:1023.
Perry HM, Perry EF. Normal concentrations of some trace minerals in human urine, changes produced by EDTA. J Clin Invest 1959;38:1452.
Perry H, Schroeder HA. Lesions resembling Vitamin B complex deficiency and urinary loss of zinc produced by EDTA. Am J Med 1957;22:168.
Demopoulos HB. Molecular oxygen in health and disease. Presented AAMP Tenth Annual Spring Meeting May 21, 1983, Los Angeles, California.
Deucher DP. EDTA chelation therapy: an antioxidant strategy. J Adv Med 1988;1:182.
Frackelton JP, Cranton EM. Iron and copper supplementation with EDTA chelation therapy. J Holistic Med 1986;8(1):63.
KIevay L. Interactions of copper and zinc in cardiovascular disease. In: OA Levander, L. Cheng. Micro-Nutrient Interactions: Vitamins, Minerals and Hazardous Elements. Ann NY Acad Sci 1980;355; 18.
Kindness G, Frackelton JP. Effect of ethylene diamine tetraacetic acid (EDTA) on platelet aggregation in human blood. J Adv Med 1989;2(4):519.
Suvorov A, Markosyan RA. Some mechanisms of EDTA on platelet aggregation. (All Union Cardiol. Res. Cent. Moscow, Russia.) Byall Eksp Biol Med 1981;(1)5:587.
Kozlov VA, Novikova VM. Calcium ion-dependent immunosuppressive effect of ethylene diamine tetraacetic acid (EDTA). Zh Mikrobiol, Epidemiol Immunobiol (Russ.) 1978;1: 69.
McDonagh EW, Rudolph CJ, Cheraskin E. The effect of intravenous disodium ethylene diamine tetraacetic acid (EDTA) upon blood cholesterol levels in a private practice environment. J Intern Acad of Prev Med 1982;7:5.
Perry HM Jr, Schroeder HA. Depression of cholesterol levels in human plasma following ethylene diamine tetraacetate and hydralazine. J Chron Dis 1955;2:520.
Schroeder HA. A practical method for the reduction of plasma cholesterol in man. J Chron Dis 1956;4:461.
Brachet P, Klein C. Cell response to CAMP during aggregation phase of Dictyostelium discoideum. Comparison of the inhibitory effects of progesterone and the stimulatory action of EDTA and ionophore A23187. Differention 1977;(8)1:1.
Goodman and Gillman's Pharmacological Basis of Therapeutics: Heavy Metals and Heavy Metal Antagonists. 1980;6:1615.
Flynn DM. 5-year controlled trial of chelating agents in treatment of thalassaemia major. Arch Dis Child 1973;48:829.
Sidbury JB Jr, Bynum JC, Fetz LL. Effect of Chelating Agent on Urinary Lead Excretion. Comparison of Oral and Intravenous Administration. Proceedings of the Society of Experimental Biology and Medicine, 1953;82: 266.
Singal PK, Kapur N, Dhillon KS, et al. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 1982;60(11):1340.
Foreman H, Trujillo T. Metabolism of carbon 14 labeled ethylenediaminetetraacetic acid in human beings. J Lab Clin Med 1954;43: 566.
Casdorph HR. EDTA chelation therapy, efficacy in arteriosclerotic heart disease. J Holistic Medicine 1981;3(1):53.
McDonagh EW, Rudolph CJ. Non invasive treatment for sequellae of failed coronary circulation: 100% occlusion of left anterior descending coronary artery, 30% stenosis right coronary artery and left ventricular contractility deficit. J Neurol Orthop Med Surg 1993;12:169.
McDonagh EW, Rudolph CJ. A collection of published papers showing the efficacy of EDTA chelation Therapy. Gladstone, MO, McDonagh Medical Center, 1991.
Casdorph HR. EDTA chelation therapy II, efficacy in brain disorders. J Holistic Medicine 1981;3(2):101.
Grumbles LA. Radionuclide studies of cerebral and cardiac arteriography before and after chelation therapy. New Horizons in Holistic Health II (Symposium). Chicago, May 27, 1979.
Olszewer E, Carter JP. Chelation therapy: a retrospective study of 2,870 patients. J Adv Med. 1989;2.5:197.
Hancke C, Flytlie K. Benefits of EDTA chelation therapy in arteriosclerosis: a retrospective study of 470 patients. J Adv Med 1993;6(3):161.
Casdorph HR, Farr CH. EDTA chelation therapy Ill: Treatment of peripheral arterial occlusion, an alternative to amputation. J Hol Med 1983;3(1):3.
McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA chelation therapy plus multivitamin/trace mineral supplementation upon vascular dynamics: ankle/brachial doppler systolic blood pressure ratio. J Hol Med 1985;7(1):16.
Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 1989;82:173.
Chappell LT, Janson M, Whitaker J. A challenge to cardiovascular surgeons. J Adv Med 1996;9(3): 153.
Birk RE, Rupe CE. The treatment of systemic sclerosis with disodium EDTA, pyridoxine and reserpine. Henry Ford Hosp Med Bull 1966;14:109
Birk RE. Treatment of systemic sclerosis. Mod Treatment 1966;3(6):1286.
Fuleihan FJD, Kurban AK, Abboud RT et al. An objective evaluation of the treatment of systemic scleroderma with disodium EDTA, pyridoxine and reserpine. Brit J Derm 1968;80:184.
Hösli P. Therapy of scleroderma with the disodium salt of ethylene diamine tetraacetic acid; a contribution to the toxicology of versenate. Part I. Arzneimittelforschung 1960;10:65
Hösli P. Therapy of scleroderma with the disodium salt of ethylenediaminetetraacetic acid; a contribution to the toxicology of versenate. Part II. Arzneimit-telforschung 1960;10:177.
Klein R, Harris SB. Treatment of scleroderma, sclerodactylia and calcinosis by chelation (EDTA). Am J Med 1955;19:798.
Mongan ES. The treatment of progressive systemic sclerosis with disodium edetate. Arthitis Rheum 1965;8:1145.
Müller SA, Brunstig LA, Winkelmann RK. The treatment of scleroderma with the new chelating agent edathamil. Arch Derm 1962;3:305.
Neldner KH, Winklemann RK, Perry HO. Scleroderma. An evaluation of treatment with disodium edetate. Arch Derm 1962;86:305.
Perry HM Jr. Chelation therapy in circulatory and sclerosing diseases. Fed Proc 1961;20(Suppl 10):254.
Winder PR, Curtis AC. Edathamil in the treatment of scleroderma and calcinosis cutis. Arch Derm 1960;82:732.
Lamar CP. Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology 1964;15:379.
Davis H, Moe PJ. Favorable response of calcinosis universalis to edathamil disodium. Pediatriacs 1959;24:780.
Herd JK, Vaughan JH. Calcinosis universalis complicating dermatomyositis, its treatment with disodium EDTA. Report of two cases in children. Arthitis Rheum 1964;7:259.
Fink CW, Baum J. Treatment of calcinosis universalis with chelating agents. Am J Dis Child 1963;105:390.
Kruck TPA, Crapper McLachlan DR. Alzheimers disease and related disorders. Alan R. Liss Inc., New York p. 1155, 1989.
Leipzig LS, Boyle AJ, McCann DS. Case histories of rheumatoid arthritis treated wiith sodium or magnesium EDTA. J Chronic Dis 1970;22:553.
Davis FA, Becker FO, Michael JA, Sorensen E. Effect of intravenous sodium bicarbonate, disodium EDTA and hyperventilation on visual and oculomotor signs in multiple sclerosis. J Neurol Neuro-surg Psychiat 1970;33:723.
Painter JT, Morrow EJ. Porphyria. Its manifestations and treatment with chelating agents. Texas State J Med 1959;55:811.
Peters H, Bichinan P, Reese H. Therapy of acute, chronic and mixed hepatic porphyria patients with chelating agents. Neurology 1958;8: 621.
Peters HA. Trace minerals, chelating agents and the porphyrias. Fed Proc 1961; 20(3) Part II Supp#10:793.
Peters HA, Johnson SAM, Cam S, Oral S, Müftü Y, Ergene T. Hexachlorobenzene-induced porphyria: Effect of chelation on the disease, porphyrin and metal metabolism. Am J Med Sci 1966;251:314.
Peters HA. Trace minerals, chelating agents and the porphyrias. Fed Proc 1961;20(Suppl 10):227.
Rotota MC, Sanowski R. Acute intermittent porphyria. J Med Soc New Jersey 1964;61:101.
Woods SM, Peters HA, Johnson SAM. Chelation therapy in cutaneous porphyria. A review and report of a five-year recovery. Arch Derm 1961;84:920.
Rosenbaum JL, Mason D, Seven, MJ. Effect of disodium ethylene diamine tetraacetic acid on digitalis intoxication. All J Ed Sci 1960;240: 77.
Surawicz B. Use of chelating agent, ethylene diamine tetraacetic acid, in digitalis intoxication and cardiac arrhythrnias. Prog in Cardiovascular Dis 1960;p. 432.
Szekely P, Wynne NA. Effects of calcium chelation on digitalis-induced cardiac arrhythmias. Brit Heart J 1963;25:589.
Klassen CD. Heavy metals and heavy metal antagonists. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 6th Ed.: 1615,1980.
Preventing lead poisoning in young children. A statement by the Centers for Disease Control, U.S. Department of Health and Human Services, Public Health Service. 1991;p.55.
Mehbod H. Treatment of lead intoxication. Combined use of peritoneal dialysis and edetate calcium disodium. JAMA 1967;201:972.
Bauer RO, Rullo FR, Spooner C, et al. Acute and subacute toxicity of ethylene diamine tetraacetic acid (EDTA) salts. Federation Proc 1952;11: 321.
Vogt W, Cottier II. Necrotizing nephrosis after treatment of a case of subacute-chronic lead poisoning with CaEDTA in high doses. Schweizerische Medizinische Wochenschrift 1957;87(22): 665.
Boyle AJ, Clarke NE, Mosher RE et al. Chelation therapy in circulatory and sclerosing diseases. Fed Proc 1961;20(3) (Part II) (suppl 10):243–257.
Dudley HR, Ritchie A, Schilling A, et al. Pathologic changes associated with the use of sodium ethylene diamine tetraacetate in the treatment of hypercalcemia. NEJM 1955;252: 331.
Reuber MD, Bradley JE. Acute versenate nephrosis occurring as the result of treatment for lead intoxication. JAMA 1960;174: 263.
Brugsch HG. Fatal cases involving EDTA (Edathamil) therapy for lead poisoning. Arch Ind Health 1959;20:285.
Craven PC, Morelli HF. Chelation therapy. West J Med, 1975;122:277.
Foreman H. Toxic side effects of ethylenediaminetetraacetic acid. J Chron Dis 1963;16:319.
Seven MJ. Observations on the toxicity of intravenous chelating agents. In: MJ Seven and LA Johnson (Eds). Metal Binding in Medicine JP Lippincot, Phila, 1960.
Schwartz SL, Johnson CB, Coolan PD. Study of the mechanism of renal vacuologenesis induced in the rat by ethylene diamine tetraacetate. Mol Pharm 1970;6:54.
Maunsbach AB, Madden S, Latta H. Light and electron microscope-changes in proximal tubules of rats after administration of glucose, mannitol, sucrose or dextran. Lab Invest 1962;11: 421.
Reuber MD, Lee CW. Calcium disodium edetate nephrosis in inbred rats. Arch Environ Health 1966;13: 544.
Schwartz SL, Hayes JR, Ide RS, et al. The nephrotoxicity of ethylenediaminete-traacetic acid. Biochem Pharmacol 1966;15: 377.
Schwartz SL, Johnson CB, Hayes JR et al. Subcellular localization of ethylene diamine tetraacetate in the proximal tubular cell by the rat kidney. Biochem Pharmacol 1967;16:2413.
Altmann J, Wakim KG, Winkelmann RK. Effects of edathamil disodium on the kidney. J Invest Dermatol 1962;38: 215.
McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: A study in serum creatinine. J Hol Med 1982;4:146.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31.
Riordan HD, Cheraskin E, Dirks M, et al. Another look at renal function and the EDTA treatment proces. J Othomol Med 1987;2(3):185.
Sehnert KW, Clague AF, Cheraskin E. The improvement in renal function following EDTA chelation and multivitamin-trace mineral therapy: A study in creatinine clearance. Med Hyp 1984;15(3):307.
Cranton EM. Kidney effects of ethylene diamine tetraacetic acid (EDTA): A literature review. J Hoi Med 1982;4:152.
Castellino N, Aloj S. Effects of calcium sodium ethylene diamine tetraacetate on the kinetics of the distribution and excretion of lead in the rat. Brit J Indust Med 1965;22:172.
Emmerson BT, Thiele BR. Calcium versenate in the diagnosis of chronic lead nephropathy. Med J Aust 1960;1: 243.
Foreman H. Use of chelating agents in treatment of metal poisoning with special emphsis on lead. Fed Proc 1961;20(Suppl 10):191.
Morgan JM. Chelation therapy in lead nephropathy. South Med J 1973;68:1001.
Rozema TC. Metabolic responses during magnesium disodium EDTA administration. Plzen. lek. Sborn 1990;Suppl. 62: 177.
Rudolph CJ, McDonagh EW. The chelation carrier solution: An analysis of osmolarity and sodium content. J Int Acad of Prev Med 1983;8(1)26.
Fine SD. Calcium disodium edetate and disodium edetate. Drugs for human use; Drug efficacy study implementation. Fed Reg 1970;(35)8.
Idaho Code Sec. 39–4305, 1975.
Perry HM Jr, Camel GH. Some effects of CaNa2 EDTA on plasma cholesterol and urinary zinc in man. In: MJ Seven and LA Johnson (Eds). Metal Binding In Medicine. JP Lippincott, Phila., 1960.
McDonagh EW, Rudolph CJ, Cheraskin E. The glycohemoglobin (HbAlc) distribution in EDTA chelation eligible patients. J Orthomol Psych 1983;12:72.
Rutman JZ, Melttzer LE, Kitchell JR, et al. Effect of metal ions on in vitro gluconeogensis in rat kidney cortex slices. Am J Physiol 1965;208:841.
Lockefeer JH, Hackeng WHL, Birkenhagër JC. Parathyroid hormone secretion in disorders of calcium metabolism studied by means of EDTA. Act Endocr 1974;75:286.
Burckhardt P, Boillat AM, Reudi B, et al. Effect of parathyroid hormone immunoheterogeneity. Schweiz Med Wochenschr 1975; (105) 50:1692.
Parfitt AM. Study of parathyroid function in man by EDTA. J Clin Endocr 1969;29:569.
Tamburino G, Fiore CE, Petralito A. Comparison of effects of EDTA (versonate) infusion on plasma calcitonin levels in senile osteoporotic and age matched healthy subjects. Ircs Med Sci: Libr Compend 1976;4(8): 362.
Peart WS, Quesada T, Tenyi T. The effects of EDTA and EGTA on renin secretion. Br J Pharmacol 1977;(59) 2: 247.
Yukimura T. Effects of EDTA and verapamil on renin secretion. Osaka-Shiritsu Daigaku Igaku Zasshi 1979;28(3): 309.
Kimmel CA. Effect of route of administration on the toxicity and teratogenicity of EDTA in the rat. Toxicol Appl Pharmacol 1977;(402:299.
Swenerton H, Hurley LS. Teratogenic effects of chelating agents and their prevention by zinc. Science 1971;Vol173;3991:62.
Foreman H, Finnegan C, Lushbaugh CC. Nephrotoxic hazard from uncontrolled edathamil calcium-disodium therapy. JAMA 1956;160:1042.
McDonagh EW, Rudolph CS, Cheraskin E. The effect of EDTA chelation therapy plus supportive multivtamin-trace mineral supplementation upon renal function: A study in blood urea nitrogen (BUN). J Hol Med 1983;5(2):163.
Bhat KR, Arunachalam J, Yegnasubramanian S et al. Trace elements in hair and environmental exposure. Sci Total Environ 1982;22(2):169.
Cranton EM. Critique of the American Medical Association's published position on hair analysis. J Hol Med 1986;8(1);47.
Cranton EM, Bland JS, Chatt A, Krakovitz R, Wright JV. Standardization and interpretation of human hair for elemental concentrations. J Hol Med 1982;4:10.
Cranton EM. Update on hair analysis in clinical medicine. J Hol Med 1986;7(2):120.
Schoenthaler SJ. Commercial hair analysis: Lack of reference norms and high reliability within and between seven selected laboratories for seventeen trace minerals. Int J Biosoc Res 1986;8(1):84.
Parry GL. Sensory Neuropathy with low dose Pyridoxine. Neurology 1985;35:1466.
Bates GW, Billups C, Saltman P. The kinetics and mechanism of iron (III) exchange between chelates and transferrin. II. The presentation and removal with ethylene diamine tetraacetate. J Biol Chem 1967;242:2816.
Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood 1976;48(3):449.
Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1(8233):1293.
Sullivan JL. Vegetarianism, ischemic heart disease, and iron, editorial, Burr ML. Reply to letter by Sullivan, editorial. Am J Clin Nutr 1983;37:882.
Willson RL. Iron, zinc, free radicals and oxygen tissue disorders and cancer control, in Iron Metabolism. Ciba Foundn Symp 51 (new series). Amsterdam, Elsevier, 1977;p 331.
Klevay LM et al. Evidence of dietary copper and zinc deficiencies. JAMA 1979;241:1916.
Prohaska JR, Lukaseqycz OA. Copper deficiency suppresses the immune response in mice. Science 1981;213:559.
Cordano A, et al. Hypocupremia and neutropenia in copper deficiency. Blood 1966;28:280.
Butterfield JD, McGraw CP. Free radical pathology. Stroke 1978;9(5):443.
Cranton EM, Frackelton JP. Free radical pathology in age associated diseases; treatment with EDTA chelation, nutrition and antioxidants. J Hol Med 1984;6: 1.
Del Maestro RF. An approach to free radicals in medicine and biology. Acta Physiol Scand 1980;492(suppl):153.
Demopoulos HB. The basis of free radical pathology. Fed Proc 1973;32:1859.
Demopoulos HB. Control of free radicals in the biologic systems. Fed Proc 1973;32: 1993.
Demopoulos HB, Pietronigro DD, Flamm ES, et al. The possible role of free radical reactions in carcinogenesis. Journal of Environmental Pathology and Toxicology 1980;3:273.
Demopoulos HB, Flamm ES, Pietronigro DD, et al. The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol Scand 1980;492(suppl):91.
Demopoulos HB, Peitronigro DD, Seligman ML. The development of secondary pathology with free radical reactions as a threshold mechanism. J Am Coll Tox 1983;2(3):173.
Rozovsky FA. Consent to treatment, a practical guide. Sec 1.10.2: 2nd ed., 1990.
Annotation, Physicians duty to inform of risks: 88ALR 3d 1008.
Zofkova I, Lambert-Allardt C, Kancheva RL et al. Effect of hypermagnesemia on the adenohypophyseal-gonadal function, parathyroid hormone secretions and some other hormonal indicators. Horm Metab Res 1993;1:29.
Zofkova I, Kancheva RL. The relationship between magnesium and calciotropic hormones. Magnes Res 1995;1:77.
Adams WJ, McGee CT. Chelation therapy: a survey of treatment outcomes and selected socio-medical factors. J Adv Med 1992;5(3):189.
Ahrens FA, Aronson AL. A comparative study of the toxic effects of calcium and chromium chelates of ethylene diamine tetraacetate in the dog. Toxic Appl Pharmac 1971;18:10.
Tandon SK. Combination therapy: a better approach to chelation in metal intoxication. Plzen.lek.Sborn. Suppl. 1988;56:187.
Ornish D. Dr. Dean Ornish's Program for Reversing Heart Disease. Random House, Inc. New York, 1990.
Pritikin, N, McGrady P. The Pritikin Program for Diet and Exercise. Grosset & Dunlap, New York, 1979.
Robbins J. Diet for a New America. Stillpoint Publishing. Walpole, NH, 1987.
Atkins RC. The Diet Revolution. M. Evans & Co., Inc. New York, 1992.
Sears B, Lawren B. Enter the Zone. Regan Books: An Imprint of Harper Collins. New York, 1995.
Klassen CD. Heavy metals and heavy metal antagonists, in Gilman AG, Goodman LS, Rall TW, Murad F (eds): The Pharmacological Basis of Therapeutics, 7th ed. New York, Macmillan, p. 1605, 1985.
Mahieu P, Buchet JP, Roels HA et al. The metabolism of arsenic in humans acutely intoxicated by As2O3. Its significance for the duration of BAL therapy. Clin. Toxicol 1981;18:1067.
Stocken LA, Thompson RM. Reactions of British antilewsite with arsenic and other metals in living systems. Physiol Rev 1949;29:168.
Eagle M, Magnuson HJ. The systemic treatment of 227 cases of arsenic poisoning (encephalitis, dermatitis, blood dyscrasias, jaundice, fever) with BAL. J Clin Invest 1946:25:420.
Oehme FW. British anti-lewsite (BAL): The classic heavy metal antidote. Clin Toxicol 1972;5:215.
Cantilewa LR, Klassen CD. The effect of chelating agents on the excretion of endogenous metals. Toxicol Appl Pharmacol 1982;63:344.
Goldfrank's Toxicologic Emergencies. Appleton & Lange, San Mateo, Ca. 1990;p 632.
Berlin M, Ullrebg S. Increased uptake of mercury in mouse brain caused by 2,3 dimercaptopropanol. Nature 1963;197:84.
Canty AJ, Kishimoto R. British anti-lewisite and organo mercury poisoning. Nature 1972;253:123.
Gillman A, Philips FS, Allen RP et al. The treatment of acute cadmium intoxication in rabbits with 2,3-dimercapropropanol (BAL) and other mercaptans. J. Pharm Exp Ther 1946b. 87:85.
Goldfrank's Toxicologic Emergencies: Appleton & Lange, San Mateo, Ca. 1990;p 621.
Handbook of Metal-Ligand Interactions in Biological Fluids. Guy Berthon ed. Marcel Dekker, Inc. N.Y., N.Y. 1995;Vol2. p. 1301.
Lund ME, Banner W Jr., Clarkson TW, Berlin M. Treatment of acute methymercury ingestion by hemodialysis with N-acetylcysteine (Mucomyst) infusion and 2,3-dimercapto propane sulfonate. J Toxicol Clin Toxicol 1984;22:31.
Parizek J, Ostadalova I. The protective effect of small amounts of selenite in sublimate intoxication. Experientia. 1967;23:142.
Magos L, Webb M, Hudson AR. Complex formation between selenium and methylmercury. Chem Biol Interact 1979;28(2–3):359.
Aposhian HV. DMSA and DMPS—Water soluble antidotes for heavy metal poisoning. Annu Rev Pharmacol Toxicol 1983;23:193.
Graziano JH. Role of 2,3 dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med Toxicol 1986;1:155.
Graziano JH, Leong JK, Friedheim E. 2,3 Dimercaptosuccinic acid: a new agent for the treatment of lead poisoning. J Pharm Exp Ther 1978;206:697.
Goldfrank's Toxicologic Emergencies Appleton & Lange, San Mateo, Ca. 1990;p. 638.
Handbook of Metal-Ligand Interactions in Biological Fluids. Guy Berthon ed. Marcel Dekker, Inc. N.Y., N.Y. 1995;Vol 2. p. 1486.
McGowan EL, Tillotson JA, Knudsen JJ et al. Biological behavior and metabolic fate of the BAL analogues DMSA and DMPS. Proc West Pharmacol Soc 1984;27:169.
Maiorino RM, Bruce DC, Aposhian HV. Determination and metabolism of dithiol chelating agents: VI. Isolation and identification of the mixed disulfides of meso-2,3-dimercaptosuccinic acid with L-cysteine in human urine. Toxicol Appl Pharmacol 1989;97:338.
Bjorksten J. Pathways to the decisive extension of the human specific lifespan. J Am Geriatrics Soc 1977;25(9):396.
Goldfrank's Toxicologic Emergencies: Appleton & Lange, San Mateo, Ca. 1990;p. 639.
Physicians Desk Reference. Medical Economics, Montvale NJ. 1996 ed; p. 1546.
Godfrey, Campbell. Personal communication.
Hruby K, Donner A. 2,3-dimercapto-l-proponesulfonate in heavy metal poisoning. Medical Toxicol 1987;2:317.
Campbell JR, Clarkson TW, Omar MD. The therapeutic use of 2,3-dimercaptopropne-1-sulfonate in two cases of inorganic mercury poisoning. J Am Med Assoc 1988; 256:3127.
Molin M, Schutz A, Skerfving S, et al. Mobilized mercury in subjects with varying exposures to elemental mercury vapour. Intl Arch Occup and Environ Health 1991;63:187.
Keberle M. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 1964;119:758.
Bertholf RL, Wills MR, Savoy J. Ultrafilterable and dialyzable aluminum in normal and uremic serum. Clin Chem 1984;30(6):972.
Sullivan JL. Sex, iron, and heart disease. Lancet 1986;2:1162.
Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989;117:1177.
Physicians Desk Reference. Medical Economics, Montvale NJ. 1996 ed.p. 820.
Lipschitz D, Dugard J, Simon M, et al. The site of action of desferrioxamine. Br J Haematol 1971;20:396.
Proper R, Nathan D. Clinical removal of iron. Ann Rev Med 1982;33:509.
Peter G, Keberle M, Schmid K. Distribution and renal excretion of desferrioxamine and ferioxamine in the dog and in the rat. Biochem Pharmacol 1966;15:93.
Goldfrank's Toxicologic Emergencies. Appleton & Lange, San Mateo, Ca. 1990;p. 285.
Westlin W. Deferoxamine in the treatment of acute iron poisoning, Clinical experiences with 172 children. Clin Pediatr 1966;5:531.
Klassen CD. Heavy metals and heavy metal antagonists. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 1980;6th Ed.: 1634.
Physicians Desk Reference. Medical Economics, Montvale NJ. 1996 ed.p. 820.
Kruck TPA, Crapper McLachlan DR. Alzheimers disease and related disorders. Alan R. Liss Inc., New York p. 1155, 1989.
Scientific American Medicine. Scientific American, Inc. Pub. 1996;Section 4, IX, p. 8.
Deiss A, Lynch RE, Lee GR et al. Long-term therapy of Wilson's disease. Ann Int Med 1971;75:57.
Walshe JM. Penicillamine, new oral therapy for Wilson's disease. Am J Med 1956;21:487.
Walshe JM. Triethylene tetramine. Lancet, 1970;2: 154.
Walshe JM. Wilson's disease presenting with features of hepatic dysfunction: A clinical analysis of eighty-seven patients. Quart J Med 1989;70:253.
Physicians Desk Reference. Medical Economics, Montvale NJ. 1996 ed.p 2664.
Kean WF, Dwosh IL, Anastassiades TP et al. The toxicity pattern of d-penicillamine therapy. Arthritis Rheum 1984;23:158.
Stein HB, Patterson AC, Offer RC et al. Adverse effects of d-penicilamine in rheumatoid arthritis. Ann Int Med 1980;92:24.
Klassen CD. Heavy metals and heavy metal antagonists. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 6th Ed.: 1627, 1980.
Schachter MB. Overview, historical background and current status of EDTA chelation therapy for atherosclerosis. J Adv Med 1996;9:159.
van der Schaar P: Brief Communication: Exercise Tolerance Tests in Chelation Therapy. J Adv Med 1989;2(4):563.
Rabau MY, Baratz M, Rozen P. Na2 ethylenediaminetetraacetic acid retention enema in dogs. Biochemical and histological response. Gen Pharmacol 1991;22(2):329.
Appendix These additional references are here for your use and edification
Ahrens FA, Aronson AL. Toxicity of calcium ethylene diamine tetreacetate in dogs. Am Soc Exp Biol 1968;27:1401.
Ahrens FA, Aronson AL. Comparative study of the toxic effects of calcium chelates of ethylenediaminetetraacetate in the dog. Tox Appl Pharmocol 1971;(18)1:10.
Alfthan G, Pikkarainen J, Huttunen JK et al. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 1982;2(8291):175.
Allen AC. The Kidney: Grune and Stratton, N.Y., p. 329, 1962.
Ames BN. Dietary carcinogens and anticarcinogens. Science 1983;221:1256.
Angle CR, McIntire MS. Lead poisoning during pregnancy. Fetal tolerance of calcium disodium edetate. Am J Dis Child 1964;108:436.
Aronov DM. First experience with the treatment of atherosclerosis patients with calcinosis of the arteries with trilon-B (disodium salt of EDTA). (Russ, Moscow) Klin Med 1963;41:19.
Aronson AL, Ahrens FA. The mechanism of renal transport and excretion of ethylenediaminetetraacetate with interspecies comparison. Toxic Appl Pharmac 1971;18:1.
Aronson AL, Hammond PB. Effect of two chelating agents on the distribution and excretion of lead. J Pharmacol Exp Ther 1964;146:241–251.
Aronson AL, Hammond PB, Strafuss AC. Studies with calcium ethylene diamine tetraacetate in calves; toxicity and use in bovine lead poisoning. Toxicol Appl Pharmacol 1968;12:337–349.
Atherosclerosis and auto oxidation of cholesterol, editorial. Lancet 1980;2:964.
Batchelor TM, McCall M, Mosher RM. Potassium diuresis induced by edathamil disodium. JAMA 1964;187:305.
Batuman V, Landy E, Maesaka JK et al. Contribution of lead to hypertension with renal impairment. N EngI J Med 1983;309(1):17.
Batuman V, Maesaka JK, Haddad B, et al. The role of lead in gout nephropathy. NEJM 1981;(304)9:520.
Bechtel JT, White JE, Estes EH Jr. The electrocardiographic effects of hypocalcemia induced in normal subjects with edathamil disodium. Circulation 1956;13:837.
Berkman N, Michaeli Y, Or R et al. EDTA dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 1991;36:195.
Birk RE, Rupe CE. Systemic sclerosis. Fourteen cases treated with chelation (disodium EDTA) and/or pyridoxine, with comments on the possible role of altered tryptophan metabolism in pathogenesis. Henry Ford Hosp Med Bull 1962;10:523.
Bjorksten J. Cross-linking—key to aging? Chem & Eng News 1955;33:1957.
Bjorksten J. The cross-linkage theory of aging as a predictive indicator. Rejuvenation 1980;8:59.
Bjorksten J. Possibilities and limitations of chelation as a means for life extension. Rejuvenation 1980;8:67.
Blake DR, Hall ND, Bacon PA et al. The importance of iron in rheumatoid disease. Lancet 1981;1:1142.
Blake DR, Hall ND, Bacon PA et al. Effect of a specific iron chelating agent on animal models of inflammation. Ann Rheum Dis 1983;42:89.
Bland JS. The utility of hair analysis: A reevaluation. J Hol Med 1983;5(1):16.
Blankenhorn DH. Calcium deposits in the plaque. In: Evolution of the Plaque. (Ed.RJ Jones) Univ Chi Press Chicago p297.
Blumer W, Reich T. Leaded gasoline—cause of cancer. Environmental International 1980;3:465.
Blumer W, Cranton EM. Ninety percent reduction in cancer mortality after chelation therapy with EDTA. JAdv Med 1989;2:183.
Bolick LE, Blankenhorn DH. A quantitative study of coronary arterial calcification. Am J Path 1961;39:511.
Boyle AJ, Jasper JJ, McCormick H, et al. Studies in human and induced atherosclerosis employing EDTA. Bull Swiss Acad Med Sci 1957;13:408.
Boyle M, Wegria R, Cathcart RT, et al. Effects of intravenous injections of nicotine on the circulation. Am Heart J 1947;34: 65.
Boyle AS, Mosher LE, McCann DS. Some in vivo effects of chelation-I: Rheumatoid arthritis. J Chronic Dis 1963;16:325.
Boyle AJ, McCann DS. New concept relating parathyroids to atherosclerotic plaque reversal. Circ Suppl 1967;2:35.
Brecher A. Bye-Bye Bypass: The Truth About Chelation Therapy. Troup, Texas, Health Savers Press, 1989.
Brien TG, Fay J. [51Cr] EDTA biological half life as an index of renal function. J Nuc Med. 1972;(13)5:339.
Brucknerova O, Tulacek J, Krojzl O. Chelates in the treatment of obliterating arteriopathies. Vnitrni Lek 1968;14:841.
Brucknerova O, Malinovska V. First clinical experience with combined treatment with chelation III and glucagon in ischemic disease of the lower extremities.Cas Lek Cas 1980;119:814.
Brucknerova O, Tulacek J. Chelates in the treatment of occlusive atherosclerosis. (Czech, Praha) Vnitr Lek 1972;18:729.
Butler AM. Use of calcium ethylenediaminetetraacetate in treating heavy-metal poisoning. Arch Indust Hyg Occupat Med 1952;7:136.
Calcium disodium edetate and disodium edetate. Drugs for human use; drug efficacy study implementation. Department of Health, Education, and Welfare. Food and Drug Adm. Federal Registrar 35 F.R. 437, 1970.
Casdorph HR. Chelation therapy: a reappraisal. N Z Med J 1983;66.
Cashion WR Jr. What about chelation? Texas Medicine 1984;80:6.
Catsch A. Radioactive metal mobilization. Fed Proc 1961;20(Suppl 10):206.
Catsch A, Harmuth-Hoene AE. Pharmacology and therapeutic applications of agents used in heavy metal poisoning. Pharmac Ther. A, 1976;1:1.
Chaitlow L. Chelation Therapy: The Revolutionary Alternative to Heart Surgery. San Francisco, Thorsons SF, 1991.
Chantler C, Barratt TM. Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child 1972;47:613.
Chantler C, Garnett ES, Parsons V et al. Glomerular filtration rate measurement in man by the single injection method using 51Cr-EDTA. Clin Sci 1969;37:169.
Chappell LT, Stahl JP. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 1993;6(3):139.
Chappell LT, Stahl JP, Evans R. EDTA chelation treatment for vascular disease: a meta-analysis using unpublished data. J Adv Med 1994;7(3):131.
Chappell LT. Chelation therapy, smoking and health care costs (Letter). J Adv Med 1994;7:107.
Chappell LT, Margolis S. Point-Counterpoint on EDTA chelation therapy. Alternative Therapies 1994;1(2):53.
Chappell LT, EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Alternative Therapies Health Med 1995;1:53.
Chappell LT, Miranda R, Rubin M et al. Chelation therapy (Letter). Circulation 1995;92:1350.
Chelation therapy (Diagnostic and therapeutic technology assessment). JAMA 1983;250:672.
Chelation therapy: a second look. The Harvard Medical School Health Letter, 1984;IX:l.
Chelation Therapy Clinic. Chelation therapy, the treatment of choice for relief from and prevention of, cardiovascular and age-related diseases. Aukland, New Zealand, The Chelation Therapy Clinic, 1987.
Chelation therapy. Resolution. 66 (I–84). AMA House of Delegates. 1984.
Chelation therapy. Report of the Council on Scientific Affairs. Report F (I–84). AMA House of Delegates. 1984.
Chelation therapy, An informal summary. Department of Health & Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland. June 1992.
Cheraskin E, Wussow DG, McDonagh EW et al. Effect of EDTA chelation and supportive multivitamin/trace mineral supplementation with and without physical activity on the heart rate. J Intern Acad of Prev Med 1984;8(6):5.
Cohen SH, Gong JK, Fishier MC. Ethylene diamine tetraacetic acid (EDTA) treatment of internal radioactive contamination. Nucleonics 1953;(11)1: 56.
Cohen S, Weissler AM, Schoenfeld CD. Antagonism of the contractile effect of digitalis by EDTA in the normal human ventricle. Am Heart J 1965;69:502.
Couric JM. Chelation therapy overdone. FDA Consumer 1982;16:28.
Cranton EM, Frackelton JP. Negative Danish Study of EDTA chelation biased. Townsend Letter for Doctors July, 1992;604–605.
Cranton EM, Frackelton JP. The current status of EDTA chelation therapy in the treatment of occlusive arterial disease. J Hol Med 1982;4: 24.
Cranton EM. Protocol of the American College of Advancement in Medicine for the safe and effective administration of EDTA chelation therapy. J Adv Med 1989;2:269.
Cranton EM. A textbook on EDTA chelation therapy. J Adv Med 1989;2:1–416.
Cranton EM. The current status of EDTA chelation therapy, editorial. J Hol Med 1985;7(1):3.
Cranton EM, Brecher A. Bypassing Bypass: The New Technique of Chelation Therapy ed 2, Medex Publishers Inc, P.O. Box 44, Trout Dale, VA 24378, 1989.
Curran CL. Metal chelating agents and hepatic cholesterol synthesis. Proc Soc Exper Biol & Med 1955;88:101.
Darwish NM, Kratzer FH. Metabolism of ethylenediaminetetraacetic acid (EDTA) by chickens. J Nutr 1965;86:187.
David O, Hoffman SP, Sverd J et al. Lead and hyperactivity, behavioral response to chelation: A pilot study. Am J Psychiatry 1976;133:1155.
Davis PS, Deller DJ. Effect of orally administered chelating agents EDTA, DTPA and fructose on radioiron absorption in man. Aust Ann Med 1967;16:70.
Deftos LJ, Goodman AD, Engleman K, et al. Suppression and stimulation of calcitonin secretion in medullary thyroid carcinoma. Metab Clin Med. 1971;(20)4: 428.
Deucher GP. Heavy metals, chelation therapy, free radicals and human disease. Angiologie, Octobre 1987.
Diagnostic and therapeutic technology assessment: Chelation therapy. JAMA 1983;250:672.
Dix T. Metabolism of polycyclic aromatic hydrocarbon derivatives to ultimate carcinogens during lipid peroxidation. Science 1983;221:77.
Donald GF, Hunter GA, Roman W et al. Current concepts of cutaneous porphyria and its treatment with particular reference to the use of sodium calcium-edetate. Brit J Derm 1970;82:70.
Donsbach KW. Chelation Therapy; Has the Plug Been Pulled on Our Biggest Killer? Huntington Beach, CA, International Institute of Health, 1981.
Doolan PD, Schwartz SL, Hayes JR, Mullen JC, Cummings NB. An evaluation of the nephrotoxicity of ethylene diamine tetraacetate and diethylene trinenine pentaacetate in the rat. Toxicol AppI Pharmocol 1967;10:481.
Dormandy TL. Free-radical reaction in biological systerms. Ann R Coll Surg Engl 1980;62:188.
Dormandy TL. Free-radical oxidation and antioxidants, Lancet 1978;1:647.
Dormandy TL. An approach to free radicals. Lancet 1983; 2:1010.
Editorial, EDTA chelation: a rebuttal. J Adv Med 1992;5:3.
EDTA chelation therapy for atherosclerotic heart disease. Medical Letter 23,1981.
EDTA chelation therapy for atherosclerotic cardiovascular disease. Medical Letter 1994;36:48.
Eliot RS, Blout SG Jr. Calcium, chelates and digitalis. A clinical study. Am Heart J 1961;62:7.
Elwood PC, Benjamin IT, Waters WE et al. Mortality and anemia in women. Lancet 1974;1:891.
Emmerson BT. Chronic lead nephropathy. The diagnostic use of calcium EDTA and the association with gout. Australian Ann Med 1963;12: 310.
Ericson JE, Shirahata H, Patterson CC. Skeletal concentrations of lead in ancient Peruvians. N Engl J Med 1979;300:946.
Estep HL, Gardner CT Jr, Taylor JP et al. Phosphate excretion patterns following intravenous injection of ethylene diamine tetraacetate ((EDTA). J Clin Endocr 1965;25:1385.
Favre HR, Wing AJ. Simultaneous 51Cr edetic acid, inulin, and endogenous creatinine clearances in 20 patients with renal disease. Brit Med J 1968;1:84.
Feigen RD, Shannon DC, Reynolds SL et al. Lead poisoning in children. Clin Pediat 1965;4:38.
Flamm ES, Demopoulos HB, Seligman ML et al. Free radicals in cerebral ischemia. Stroke 1978;9(5):445.
Flytlie K, Hancke C. Letter to the editor: EDTA manipulated. J Adv Med 1993;6(1):53.
Foote CS. Chemistry of singlet oxygen VII. Quenching by beta carotene. J Am Chem Soc 1968;90:6233.
Foreman H. The use of chelating agents for excelerating excretion of radioelements. J Am Pharm Assoc 1953;42: 629.
Foreman H. Summary remarks by the chairman. [Proceedings of a conference on biological apects of metal-binding.] Fed Proc 1961;20(Suppl 10):257.
Foreman H, Vier M, Magee M. The metabolism of C14 labeled ethylenediaminetetraacetic acid in the rat. J Biol Chem 1953;203:1045.
Foreman H, Hardy H, Shipman T, et al. Use of calcium ethylene diamine tetraacetate in cases of lead intoxication. Am Archiv Indust Hyg Occup Med 1953;7: 148.
Forssman O, Nordqvist P. The action in vitro and in vivo of sodium versenate on the phagocytic activity of neutrophile leukocytes. Acta Haemat 1964;31:289.
Frackelton JP. Monitoring renal function during EDTA chelation therapy. J Hol Med 1986;8(1):33.
Friedel W, Schulz FH, Schroder L. Therapy of atherosclerosis through mucopolysaccarides and EDTA (ethylene diamine tetraacetic acid). (German) Deutsch Gesundh 1965;20:1566.
Fromke VL, Lee MY, Watson CJ. Porphyrin metabolism during Versenate* therapy in lead poisoning. Intoxication from an unusual source. Ann Intern Med 1969;70: 1007.
Gaby AR. Nutritional factors in cardiovascular disease. J Holistic Medicine 1983;5(2): 107.
Gerstenblith G, Ouyang P, Achuff S, et al. Nifedipine in unstable angina: A double-blind, randomized trial. NEJM 1982;(306)15: 885.
Gibbons HL. Edetate disodium calcium, calcium-channel blockers, and heart disease. JAMA 1981;246:1728.
Gibson T. Letter to the editor: chelation therapy. N Z Med J 1982;95:653.
Gibson T. Letter to the editor: The benefits of EDTA chelation therapy for atherosclerosis. Med J Australia 1985;143(3):127.
Gibson T. Letter to the editor: chelation therapy. N Z Med J 1988;9:182.
Godfrey ME. EDTA chelation as a treatment of arteriosclerosis. N Z Med J 1990;93: 199.
Godfrey ME, Frackleton JP, Chappell LT. Chelation therapy for intermittent claudication (Letter). N Z Med J 1994;107:495.
Godfrey ME, Agnihotri R, Strauss A. Chelation and arteriosclerosis. N Z Med J 1988;101(838):21.
Goetzl EJ. Oxygenation products of arachidonic acid as mediators of hypersensitivity and inflammation. Med Clin North Am 1981;65(4):809.
Goldfrank's Toxicologic Emergencies: Appleton & Lange, San Mateo, Ca. 1990;p. 646.
Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707.
Gordon GB, Vance RB. EDTA chelation therapy for atherosclerosis: History and mechanisms of action. Osteopathic Annals 1976;4:38.
Gordon GF. Oral chelation with EDTA. J Holistic Medicine 1986;8(1):79.
Gordon T, Kannel WB, Hjortland MC et al. Menopause and coronary heart disease. The Framingham Study. Am Intern Med 1978;89:157.
Gotto AM Jr. Chelation therapy in 1984. Texas Medicine, 1984;80:36.
Gould RG. Metals and chelating agents in relation to atherosclerosis. Fed Proc 1961;20(Suppl 10):252.
Grier MT, Meyers DG. So much writing, so little science: A review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 1993;27:1504.
Guldager B, Jelnes R, Jorgenson SJ, et al. EDTA treatment of intermittent claudication—a double-blind placebo-controlled study. J Intern Med 1992;231:261.
Gutteridge JMC, Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Biochem J 1982;206:605.
Gutteridge JMC, Rowley DA, Halliwell B et al. Increased non-protein-bound iron and decreased protection against superoxide radical damage in cerebrospinal fluid from patients with neuronal ceroid lipofuscinoses. Lancet 1982;2:459.
Hancke C, Flytlie K. Manipulation with EDTA. Ugeskr Laeger 1992;154:2213.
Hansotia P, Peters H, Bennett M et al. Chelation therapy in Wegener's granulomatosis. Treatment with EDTA. Ann Otol 1969;78:388.
Hardy HL. Clinical experience with the use of calcium disodium ethylene diamine tetraacetate in the therapy of lead poisoning. Fed Proc 1961;20(Suppl 10):252.
Harman D. The aging process. Proc Natl Acad Sci USA 1981;78:7124.
Harper JW, Gordon GF. Reprints of Medical Literature on Chelation Therapy. Los Angeles, American Academy of Medical Preventics, 1975.
Hart H, Lazlo D. Modification of the distribution and excretion by radioisotopes by chelating agents. Science 1953;118:24.
Hatano S, Nishi Y, Usui T. Copper levels in plasma and erythrocytes in healthy Japanese children and adults. Am J Clin Nutr 1982;35:120.
Haumont S, Vincent J. Action of calcium versenate on lead fixed in vivo in compact bone. Exp Cell Res 1959;18:404.
Hausmann E. Changes in plasma phosphate concentration on infusion of calcium gluconate or Na2EDTA. Proc Soc Exp Biol Med 1970;134:182.
Hay DR. Chelation therapy. N Z Med J 1988;101(841):122.
Hay DR. Chelation therapy. N Z Med J 1988;101(845):246.
Heath DA, Knapp MS, Walker WHC. Comparison between inulin and 51Cr-labelled edetic acid for the measurement of glomerular filtration-rate. Lancet 1968;2: 1110.
Hegsted DM. Major minerals. Section A. Calcium and phosphorus. In: RS Goodheart and ME Shields (Eds.). Modern Nutrition in Health and Disease. Lea and Febiger, Phila., 1974;p. 266.
Heller J, Vostal J. Renal excretion of calcium disodium ethylene diamine tetraacetic acid, a new tubular secretory mechanism? Experientia 1964;20:99.
Hess ML, Manson NH, Okabe E. Involvement of free radicals in the pathophysiology of ischemic heart disease. Can J Physiol Pharmacol 1982;60(11):1382.
Hjortland MC, McNamara PM, Kannel WB. Some atherogenic concomitants of menopause: The Framingham Study. Am J Epidemiol 1976;103:304.
Holland JF, Danielson E, Sahagian-Edwards A. Use of EDTA in hypercalcemic patients. Proc Soc Exp Biol Med 1953;84:359.
HoIm LW. The use of calcium disodium salt of Versene in heavy-metal poisoning of livestock. Proc Am Vet Med Assoc 1954;48: 33.
Jenkins DW. Toxic Trace Metals in Mammalian Hair and Nails. US Environmental Protection Agency publication No. (EPA)-600/4-79-049. Environmental Monitoring Systems Laboratory, 1979. (Available from National Technical Information Service, U.S. Department of Commerce, Springfield, Virginia 22161.).
Jick S, Karsh R. The effect of calcium chelation on cardiac arrhythmias and conduction disturbances. Am J Cardiol 1959;4:287.
Johnson SAM. Use of the chelating agent edathamil disodium in acrosclerosis, sarcoidosis and other skin conditions with comments on tryptophan metabolism in sarcoidosis. Wisconson Med J 1960;59:651.
Jonas WB. Meta-analysis of EDTA chelation: Math that doesn't matter. J Adv Med 1994;7:109.
Jonas WB. Effectiveness of EDTA chelation therapy. Circulation 1995;5:1352.
Jones RJ. Chelation therapy (Letter). JAMA 1983;250:672.
Julian JJ. Pass or Bypass? Chelation Extends Life. Hollywood, Wellness Press, 1981.
Kalliomaki JL, Markkanen TK, Mustonen VA. Serum calcium and phosphorous homeostasis in man studied by means of the sodium EDTA test. Acta Med Scan 1961;170:211.
Kaman RL, Rudolph CJ, Mcdonagh EW et al. Effect of EDTA chelation therapy on aortic calcium in rabbits on atherogenic diets: quantitative and histochemical studies. J Adv Med 1990;3(1):13.
Kapoor SC, Wielopolski L, Graziano JH et al. Influence of 2,3-dimercaptosuccinic acid on gastrointestinal lead absorption and whole-body lead retention. Toxicol Appl Pharmacol 1989;97:525.
Kannel WB, Hjortland MC, McNamara PM et al. Menopause and the risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976:85:447.
Kebe SR. ACTH and a chelating agent for schizophrenia. West Med 1963;4:46.
Kehoe RA. Value of calcium disodium ethylene diamine tetraacetate and British Antilewisite in therapy of lead poisoning. Fed Proc 1961;20(3) Part II Supp#10: 196.
Kety SS, Letnoff TV. Treatment of lead poisoning with sodium citrate. Proc Soc Exp Biol & Med 1941;46:476.
Kitchell JR, Meltzer LE, The potential uses of EDTA chelation therapy in the treatment of cardiovascular diseases. Prog of Cardiovascular Dis 1961;3:338.
Kitchell JR, Palmon F, Aytan N et al. The treatment of coronary artery disease with disodium EDTA, a reappraisal. Am J Cardiol 1963;11:501.
Klevay L. Hair as a biopsy material-assessment of copper nutriture. Am J Clin Nutr 1970;23(8):1194.
Kneller LA, Uhl HSM, Brem J. Successful calcium disodium ethylene diamine tetraacetate treatment of lead poisoning in an infant. N Engl J Med 1955;252:338.
Koen A, McCann DS, Boyle AJ. Some in vivo effects of chelation. II. Animal experimentation. J Chron Dis 1963;16:329.
Lamar CP. Chelation endarterectomy for occlusive atherosclerosis. J Am Geri Soc 1966;14(3):272.
Lamar CP. Calcium chelation of atherosclerosis, nine years' clinical experience. Read before the Fourteenth Annual Meeting of the American College of Angiology, San Juan, PR, Dec 8, 1968. (Transcript available from ACAM, 23121 Verdugo Dr., Suite 204, Laguna Hills, CA 92653.).
Lamb DJ, Leake DS. The effect of EDTA on the oxidation of low density lipoprotein. Atherosclerosis 1992;94:35.
Leitner SA. Last chance to live. Wade Allen Publishing, Chesterfield, MO, 1980.
Lelievre P, Betz EH. Effect of versene on oxygen consumption of tissues in vitro. C R Soc Biol 1961;155:199.
Levine SA, Kidd PM. Antioxidant Adaptation: It's Role in Free Radical Pathology. San Leandro, California, Biocurrents, 1985.
Liberman UA, Barzel U, De Vries A et al. Myositis ossificans traumatica with unusual course. Effect of EDTA on calcium, phosphorus and mangenese excretion. Am J Med Sci 1967;254:35.
Lochte HL Jr, Ferrebee JW, Thomas ED. The effect of heparin and EDTA on DNA synthesis by marrow in vitro. J Lab Clin Med 55435, 1960.
Lonsdale D. EDTA chelation therapy. Am J Surg 1993;166:316.
Luchi RJ, Helwig J Jr, Conn HL Jr. Quinidine toxicity and its treatment. An experimental study. Am Heart J 1963;65:340.
Lyons RD. Chelation: miracle cure or false hope? Med J Aust 1985;142: 519.
Magee HR. Chelation therapy for atherosclerosis. Med J Aust 1985;143:127.
Magee HR. Chelation treatment of atherosclerosis. Med J Aust 1985;142:514.
Malinovska V, Zechmeister A, Brucknerova E et al. Ultrahistochemical study of the effect of glucagon and Chelation III on arterial wall structure after experimental calcification. Folia Morphologica 1978;28:20.
Malinovska V, Zechmeister A, Malinovsky L et al. The therapeutic effect of glucagon and chelation III (EDTA) on the arterial wall after experimental lipidosis and calcification. Scripta Medica 1983;56(7):391.
Marcelle R, Lecomte J. On the cardiovascular activities of the sodium salt of ethylene diamine tetraacetic acid. C R Soc Biol 1959;153:1483.
Margolis S. Chelation therapy is ineffective for the treatment of peripheral vascular disease. Alt Therapies Health Med 1955;1:53.
Marlow CG, Sheppard G. [51Cr] EDTA, [hydroxymethyl-14C] inulin-T for the determination of glomerular filtration rate. Clin Chim Acta 1970;28:479.
Marney SR Jr, Des Prez RM. Rabbit platelet injury by soluble antigen and antibody. III. Effects of the sodium and magnesium salts of EDTA and EGTA. J Immun 1971;106:1446.
Marsh L, Fraser FC. Chelating agents and teratogenesis. (Letter) Lancet 1973;1:846.
Maxwell GM, Elliot RB, Robertson E. The effect of Na3EDTA-induced hypocalcemia upon the general and coronary hemodynamics of the intact animal. Am Heart J 1963;66:82.
Mayan H, Salomon O, Pauzner R, et al. EDTA induced pseudothrombocytopenia. South Med J 1992;85:213.
Meltzer L, Kitchell J, Palmon F. The long term use, side effects, and toxicity of disodium ethylelene diamine tetraacetic acid (EDTA). Am J Med Sci 1961;242: 11.
Meltzer LE, Ural, ME, Kitchell JR. The treatment of coronary artery disease with disodium EDTA. in: Seven JJ, Johnson LA (eds): Metal Binding in Medicine. JB Lipincott Co Philadelphia 1960;ppl32.
McCann DS, Koen Z, Zdybek G et al. Effect of chelation on phosphorus metabolism in experimental atherosclerosis. Circ Res 1962;11:880.
McCoy JE, Carre IJ, Freeman M. A controlled trial of edathamil calcium disodium in acrodynia. Pediatrics 1960;25:304.
McDonagh E. Circulation changes in extremities with chelation therapy. Paper presented at American Academy of Medical Preventics Fall Conference, Las Vegas, Nevada, November, 1982.
McDonagh EW, Rudolph CJ, Cheraskin E. The Influence of EDTA salts plus multivitamin-trace mineral therapy upon total serum cholesterol/high-density lipoprotein cholesterol. Med Hypotheses 1982;9:643.
McDonagh EW, Rudolph CJ, Cheraskin E. The homeostatic effect of EDTA with supportive multivitamin trace mineral supplementation upon high-density lipoproteins (HDL). J Osteopath Phys Surg Calif 1982;8:2.
McDonagh EW, Rudolph CJ, Cheraskin E. The effect of intra-venous disodium ethylene diamine tetraacetic acid (EDTA) plus supportive multivitamin/trace mineral supplementation upon fasting serum calcium. Med Hypotheses 1982;11:431.
McDonagh EW. Chelation can cure: How to reverse heart disease, diabetes, stroke, high blood pressure or surgery. Kansas City, Platinum Pen Publications, 1983.
McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA chelation therapy with multivitamin/trace mineral supplementation upon reported fatigue. J Orthomol Psy 1984;13(4):1.
McDonagh EW, Rudolph CJ, Cheraskin E et al. The effect of EDTA chelation and supportive multivitamin/trace mineral supplementation with and without physical activity upon systolic blood pressure. J Orthomol Psy 1984;13;1.
McDonagh EW, Rudolph CJ, Cheraskin E. The psychotherapeutic potential of EDTA chelation. J Orthomol Psy 1985;14(3):214.
McDonagh EW, Rudolph CJ, Cheraskin E. The clinical changes in patients treated with EDTA chelation plus multivitamin/trace mineral supplementation. J Orthomol Psy 1985;14(1):61.
McDonagh EW, Rudolph CJ, Cheraskin E. An oculocerebrovasculometric analysis of the improvement in vascular stenosis following edta chelation therapy. J Hol Med 1982;4(1): 21.
McGill WF. The effects of EDTA chelation therapy on plaque calcium and mineral metabolism in atherosclerotic rabbits. Dissertation Abstracts International 1980;Vol. 41, No. 04.
McGillem MJ, Mancini GB. Inefficacy of EDTA chelation therapy for coronary atherosclerosis. N Eng J Med 1988;318:1618.
Meltzer LE. Chelation Therapy. In Seven MJ, Johnson LA (eds): Metal Binding in Medicine. Philadelphia, JB Lippincott, 1960.
Meltzer LE, Palmon FJ, Kitchell JR. Hypoglycemia induced by disodium ethylenediamine tetra-acetic acid. 1961;Lancet 2:637.
Meltzer LE, Kitchell JR, Palmon FJ. The long term use, side effects, and toxicity of disodium ethylene diamine tetraacetic acid (EDTA). Am J Med Sci 1961;242:11.
Meltzer LE, Ural ME, Kitchell JR. The treatment of coronary artery disease with disodium EDTA, in Seven MJ, Johnson, LA (eds): Metal Binding in Medicine. Philadelphia, J.B. Lippencott Co, 1960, p 132.
Mischol HR, Wildbolz R. Instrumental chemolysis of renal calculi: Indications and dangers. J Urol 1971;105:607, 1971.
Moel DI, Kunar K. Reversible nephrotoxic reactions to a combined 2,3-dimercapto-l-propanol and calcium disodium ethylene diamine tetraacetic acid regimen to asymptomatic children with elevated blood lead levels. Pediatrics 1982;70:259.
Monaco GP, Green S. Recognizing deception in the promotion of untested and unproven medical treatments. NY State J of Med 1993;2:88.
Moncrieff AA, Koumides OP, Clayton BE et al. Lead poisoning in children. Arch Dis Child 1964;39:1.
Montgomery MR. Advances in medical fraud: chelation therapy replaces Laetrile. J Florida Med Assoc 1986;73:681.
Morgan GT, Drew HDK. Researches on residual affinity and coordination. Pt II. acetylacetones of selenium and tellurium. J Chem Soc (London) 1920;117:1456.
Myers HL. Topical chelation therapy for varicose pigmentation. Angiology 1966;17:66.
Myslak Z, Buczkowski M. Effect of calcium versenate upon kidneys during saturnism therapy. Pol Arch Med Wewnettrzmej 1961;(31); 853.
Nakano J, Cole B, Ishii T. Effects of disodium EDTA on the cardiovascular responses to prostaglandin E1. Experientia 1968;24:808.
Nayler WG. Ventricular arrhythmias following the administration of Na2EDTA. J Pharmacol Exp Ther 1962;137:5.
Nedergaard OA, Vagne A. Effect of EDTA and other chelating agents on norepinephrine uptake by rabbit aorta in vitro. Proc West Pharmacol Soc 1968;11: 87.
Nguyen-The-Minh. Treatment of digitalis intoxication with EDTA Na2. Presse Med 1963;71:2385.
Nikitina EL, Abramova MA. Treatment of atherosclerosis patients with Trilon-B (EDTA). (Russ, Moscow) Kardiologiia 1972;12:137.
Nodine JH. Edetic acid therapy. (Letter) JAMA 1970;212:628.
Nolan KR. Copper toxicity syndrome. J Orthomol Psychiatr 1983;12(4):270.
Oehme FW. British anti-lewsite (BAL): The classic heavy metal antidote. Clin Toxicol 1972;5:215.
Offer GW. The antagonistic action of magnesium ions and ethylene diamine tetraacetate on myosin A ATPase (potassium activated). Biochim Biophys Acta 1964;89: 566.
Oliver LD, Mehta R, Sarle HE. Acute renal failure following administration of ethylene diamine tetraacetic acid (EDTA). Texas Medicine February 1984;80:40.
Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Medical Hypothesis 1988;27:41.
Olwin JH, Koppel JL. Reduction of elevated plasma lipid levels in atherosclerosis following EDTA therapy. Proc Soc Exp Biol Med 1968;128:1137.
Ontka JA. Physical and chemical changes in isolated chylomicrons: prevention by EDTA. J Lipid Res 1970;11:367.
Orimo H, Ouchi Y. The role of calcium and magnesium in the development of atherosclerosis; experimental and clinical evidence. Annals New York Academy of Sciences 1991:p444.
Oser BL. Observations on the chronic ingestion of a chelating agent by rats and dogs. Fed Proc 1961;20(Suppl 10):158.
Oser BL, Oser M, Spencer HC. Safety evaluation studies of calcium EDTA. Toxicol Appl Pharmacol 1963;5:142.
Passwater RA, Cranton EM. Trace Elements, Hair Analysis and Nutrition. New Canaan, CT, Keats Publishing Inc, 1983.
Patterson R. Chelation therapy and Uncle John. CMAJ 1989;140(7):829.
Pavek K, Drinal J, Selecky FV. Circulatory effects of disodium edetate in digoxin-induced ventricular tachycardia. Cardiologia 1967;50:297.
Payne RB. Creatinine clearance: A redundant clinical investigation. Ann Clin Biochem 1986;23:243.
Payne JM, Sansom BF. The relative toxicity in rats of disodium ethylene diamine tetraacetate, sodium oxalate and sodium citrate. J Physiol 1964;170:613.
Peng CF, Kane JJ, Murphy ML et al. Abnormal mitochondrial oxidative phosphorylation of ischemic myocardium reversed by calcium chelating agents. J Mol Cell Cardiol 1977;9:897.
Pentel P, Jorgensen C, Somerville J. Chelation therapy for the treatment of atherosclerosis, an appraisal. Minn Med Feb 1984;101.
Peters RA, Stocken LA, Thompson RHS. British Anti-Lewisite (BAL). Nature 1945; 156:616.
Peterson CR. Adverse effects of chelation therapy. JAMA 1983;250:2926.
Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature 1981;290:201.
Petrovic L, Stanovic M, Savicevic M et al. Aerosol inhaltion of CaNa2EDTA (mosatil) by workers constantly exposed to lead poisoning. Brit J Indust Med 1960;17:201.
Pietronigro DD, Demopoulos HB, Hovsepian M et al. Brain ascorbic acid (AA) depletion during cerebral ischemia. Stroke 1982;13(1):117.
Platts-Mills A. EDTA chelation therapy. NZ Med J, 1988;101(849):465.
Popovici A, Rubin M. EDTA as an anticoagulant in clinical laboratory studies. Soc Exper and Biol Med 1950;74:415.
Povoa H, Dantas LS, Faine R et al. Antioxidant stimulation of phagocytosis using mannitol as a free radical scavenger. J Advancement Med 1988;1(3):143.
Price JM. Some effects of chelating agents on tryptophan metabolism in man. Fed Proc 1961;20(Suppl 10):223.
Proceedings: Hearing on EDTA Chelation Therapy of the Ad Hoc Scientific Advisory Panel on Internal Medicine of the Scientific Board of the California Medical Society, March 26, 1976, San Francisco, California (Transcript available ACAM, 23121 Verdugo Dr., Suite 204, Laguna Hills, CA 92653.
Pullman TN, Lavender AR, Forland M. Synthetic chelating agents in clinical medicine. Ann Rev Med 1963;14:175.
Rabau MY, Baratz M, Rozen P. Na2 ethylenediaminetetraacetic acid retention enema in dogs. Biochemical and histological response. Gen Pharmacol 1991;22(2): 329.
Rathmann KL, Golightly LK. Chelation therapy of atherosclerosis. Drug Intell Clin Pharm 1984;18:1000.
Raymond JZ, Gross PR. EDTA: preservative dermatitis. Arch Derm 1969;100:436.
Rees EL. Aluminum poisoning of Papua New Guinea natives as shown by hair testing. J Orthomol Psychiatry 1983;12(4):312.
Reidenberg MM. Kidney function and drug action. N Eng J Med 1985;313:816.
Remagen W, Hiller FK, Sanz CM. Metabolic changes in experimental poisoning with ethylenediamine-tetraacetic acid. Arzneimittelforschung 1961;11:1097.
Renoux M, Mikol C. Chelation. Presse Med 1964;72:3117.
Reuber MD. Accentuation of Ca edetate nephrosis by cortisone. Arch Path 1963;76:382.
Reuber MD. Severe nephrosis in older male rats given calcium disodium edetate. Arch Environ Health 1967;15:141.
Reuber MD, Schmieler GC. Edetate kidneys lesions in rats. Arch Environ Health 1962;5:430.
Reuber MD. Hepatic lesions in young rats given calcium disodium edetate. Toxicol Appl Pharmacol 1967;11:321.
Reuter H, Niemeyer G, Gross R. The distribution of EDTA and citrate in blood and plasma. Throm Diath Haemorrh 1968;19:213.
Rieders F, Dunnington WG, Brieger H. The efficacy of edathamil calcium disodium in the treatment of occupational lead poisoning. Indust Med 1955;24:195.
Riordan HD, Cheraskin E, Dirks M, et al. EDTA chelation/hypertension study: clinical patterns as judged by the Cornell Medical Index Questionnaire. J Orthomol Med 1989;4:91.
Riordon HD, Cheraskin E, Dirks M, et al. Electrocardiographic changes associated with EDTA chelation therapy. J Adv Med 1988;1:191.
Robinson DM. Chelation therapy. N Z Med J 1982;74:750.
Rosenman RH, Smith MK. The effect of certain chelating substances (EDTA) upon cholesterol metabolism in the rat. J Clin Invest 1956;35:11.
Rossi EC. Effects of ethylene diamine tetraacetic acid (EDTA) and citrate upon platelet glycolysis. J Lab Clin Med 1967;69:204.
Rubin M, Gignac S, Bessman SP et al. Enhancement of Lead Excretion in Humans by Disodium Calcium Ethylenediamine Tetraacetate. Science 1953;117: 659.
Rubin M, Scarchilli AJ, Rozema T, Casdorph R. Cardiac decalcification by Na2EDTA. Am Soc Med Chem Aug 23, 1994.
Rudolph CJ, McDonagh EW, Barber RK. Effect of EDTA chelation and supportive multivitamin/trace mineral supplementation on chronic lung disorders: a study of FVC and FEV1. J Adv Med 1989;2(4): 553.
Rudolph CJ, McDonagh EW, Barber RK. The effect of EDTA chelation on serum iron. J Adv Med 1991;4:39.
Rudolph CJ, Samuels RT, McDonagh EW. Visual field evidence of macular degeneration reversal using a combination of EDTA and multiple vitamin and trace mineral therapy. J Adv Med 1994;7:203.
Rudolph CJ, McDonagh EW. Effect of EDTA chelation and supportive multivitamin trace mineral supplementation on carotid circulation: case report. J Adv Med 1990;3(1):5.
Rudolph CJ, Mcdonagh EW, Barber RK. A nonsurgical approach to obstructive carotid stenosis using EDTA Chelation. J Adv Med 1991;4(3):157.
Rudolph CJ, Mcdonagh EW, Barber RK. An observation of the effect of EDTA chelation and supportive multivitamin/trace mineral supplementation on blood platelet volume: a brief communication. J Adv Med 1990;3(3):179.
Sachs HK, Blanksma LA, Murray EF et al. Ambulatory treatment of lead poisoning: report of 1,155 cases. Pediatrics 1970;46:389.
Salonen J, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 1992;86(3):803.
Saunders JF, Princiotto JV, Rubin M. Effect of calcium disodium ethylene diamine tetraacetate on hypercholesterolemic rabbits. Soc Exp Biol & Med 1956;92:29.
Schachter MB. Letter to the editor: chelation therapy. Circulation 1995;91(4):2291.
Schachter MB. Health fraud versus innovation-a letter to the editor. J Adv in Med 1993;6(3):198.
Schroeder HA. The Poisons Around Us. Bloomington, IN, Indiana University Press, 1974.
Schroeder HA, Menhard EM, Perry HM Jr. Antihypertensive effects of metal binding agents. J Lab & Clin Med 1955;23:416.
Schubert J. Chelation in medicine. Sci Am 1966;214:40.
Schubert J. Radioelement removal by chelating agents: application of mass action laws and other factors. Fed Proc 1961;20(3) Part II Supp#10:206.
Scott PJ. Chelation therapy for degenerative vascular disease. N Z Med J 1982;95:538.
Scott PJ. Chelation therapy: evolution or devolution of a nostrum? N Z Med J 1988;101:109.
Seelig M. Magnesium Deficiency in the Pathogenesis of Disease Plenum Press, NY, 1980.
Selander S. Treatment of lead poisoning. A comparison between the effects of sodium calcium edetate and penicillamine administered orally and intravenously. Brit J Indust Med 1967;24:272.
Seto DSY, Freeman JM. Lead nephropathy in childhood. Am J Dis Child 1964;107:337.
Seven MJ, Johnson LA. Metal Binding in Medicine, JB Lippincott, Phila, 1960.
Shaw D. Letter to the editor-chelation therapy. N Z Med J 1983;96:144.
Shibata S. Toxicological studies of EDTA salt (sodium ethylenediamine tetra-acetate. Folia Pharmacol Japonica 1956;52:113.
Shibata S. Toxicological studies of EDTA salt (sodium ethylenediamine tetra-acetate. Chem Abst 1957;51:9918.
Shrand H. Treatment of lead poisoning with intramuscular edathamil calcium-disodium. Lancet 1961;1:310.
Silverglade A. Chelation clinics. Chest 1985;87:274.
Sincock A. Life extension in the rotifer by application of chelating agents. J Gerontol 1975;30:289.
Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 1991;162:122.
Soffer A. Chelation therapy for arteriosclerosis. JAMA 1975;233:1206.
Soffer A. Chihuahuas and laetrile, chelation therapy, and honey from Boulder, Colo. Arch Intern Med 1976;136:865.
Soffer A. Chelation clinics, an abuse of the physician's freedom of choice. Chest 1984;86:157.
Soffer A, Toribara T. Changes in serum and spinal fluid calcium effected by disodium ethylene diamine tetraacetate. J Lab Clin Med 1961;58: 542.
Soffer A. Chelation Therapy. Charles C. Thomas, Springfield, IL, 1964.
Soffer A, Toribara T, Sayman A. Myocardial responses to chelation. Brit Heart J 1961;23:690.
Soffer A, Toribara T, Moore-Jones D et al. Clinical applications and untoward reactions of chelation in cardiac arrhythmias. Arch Inten Med 1960;106:824.
Smith LL. Cholesterol Autooxidation. New York Plenum Press, 1981.
Spence JD. Chelation therapy for intermittent claudication. ACP Journal Club, 1992; July/August p8.
Spencer H. Studies of the effect of chelating agents in man. Ann NY Acad Sci 1960; 88:435.
Stacey BD, Thorborn GD. Chromium-51 ethylenediaminetetraacetate for estimation of glomerular filtration rate. Science 1966;152:1076.
Stamp TCB, Stacey TE, Rose GA. Comparison of glomerular filtration rate measurements using inulin, 51Cr-EDTA, and a phosphate infusion technique. Clin Chim Acta 1970;30:351.
Stamp TCB. 51Cr-edetic-acid clearance and G.F.R. (Letter) Lancet 1968;2:1348.
Stankovic D, Keser-Stankovi M. Effects of EDTA on liver and kidneys and protective effects of EDTA on these organs in animals treated with lead. Folia Med 1979; 14:101.
Stecker RH, Bennett M. Chelation in clinical otosclerosis. Arch Otolaryng 1959;70:627.
Steven FS. The effect of chelating agents on collagen interfibrillar matrix interactions in connective tissue. Biochim Biophys Acta 1967;140:522.
Stevenson JG, Covington TR. Chelation therapy in atherosclerosis. Ann Intern Med 1982;97:789.
Stimson WH. Vitamin A intoxication in adults. Reportof a case with summary of the literature. New Eng J Med 1961;265: 369.
Sullivan JL. Iron, aspirin and heart disease risk, editorial. JAMA 1982;247(6):751.
Sullivan JL. The sex difference in ischemic heart disease. Perspectives in Biol Med 1983;26:657.
Surawicz B, MacDonald MG, Kaljot V, et al. Treatment of cardiac arrythmias with salts of ethylenediaminetetraacetic acid (EDTA). Am Heart J 1959;58: 493.
Surawicz B, MacDonald MG, Kaljot V et al. The effect of intravenous administration of disodium and dipotassium EDTA on cardiac arrhythmias. In: Seven MJ and Johnson LA (Editors) Metal-binding in Medicine, JB Lippincott Co. Philadelphia, 1960.
Tappel AL. Will antioxidant nutrients slow aging processes? Geriatrics 1968;23:97.
Tappel AL. Lipid peroxidation damage to cell components. Fed Proc 1973;32:1870.
Tappel L. Vitamin E and Selenium Protection from In Vivo lipid peroxidation. Micronutrient Interactions: Vitamins, Minerals, and Hazardous Elements. OA L Cheng I Acad Sci 1981;355: 18.
Tate SS. Effect of metal ions and EDTA on the activity of rabbit liver fructose 1,6-diphosphatase Biochim Biophys Res Commun 1966;24:662.
Taylor CB, Peng SK, Werthessen NT et al. Spontaneously occurring angiotoxic derivatives of cholesterol. Am J Clin Nutr 1979;32:40.
Teisinger J. Biochemical responses to provocative chelation by edetate disodium calcium. Arch Environ Health 1971;23:280.
Thatcher RW, Lester ML, McAlester R, Horst R. Effects of low levels of cadmium and lead on cognitive functioning in children. Arch Environ Health 1982;37(3):159.
The Committee on Scientific Dishonesty (UVVU): Conclusion concerning complaints in connections with trial of EDTA versus placebo in the treatment of arteriosclerosis. Danish Research Councils.
Thompson LJ. Chelation therapy. N Z Med J 1990;103:326.
Timmerman A, Kallistratos G, Genner O. In situ lysis of kidney stones. Urologic technique and drugs. Congr Int Ther 161–75.
Timmermann A, Kallistratos G. Chemotherapy in nephrolithiasis. Isr J Med Sci 1971;7:689.
Timmermann A, Kallistratos G. Modern aspects of chemical dissolution of human renal calculi by irrigation. J Urol 1966;95:469.
Traub YM, Samuel R, Lubin E et al. A comparison between the clearances of inulin, endogenous creatinine, and 51Cr-EDTA. Isr J Med Sci 1973;9:487.
Trowbridge W, Walker M. Chelation Therapy: The Key to Unclogging Your Arteries, Improving Oxygenation, Treating Vision Problems. 3rd Ed. Marble Falls, Texas, Better Health Booklet Service, 1990.
Truss F. Clinical significance of kidney stone chemolysis. Kidney tolerance to ethylene diamine tetraacetic acid (EDTA). Med Welt 1971;7: 238.
Uhl HSM, Brown HH, Zlatkis A et al. Effect of ethylene diamine tetraacetic acid on cholesterol metabolism in rabbits. Am J Clin Path 1950;23:1226.
van der Schaar P. Brief Communication: Exercise Tolerance Tests in Chelation Therapy. J Adv Med 1989;2(4): 563.
van Rij AM, Solomon C, Packer SGK, et al. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 1994;90: 1194.
van Rij AM, Solomon C, Packer SGK et al. [Effectiveness of EDTA chelation therapy] Response (Letter). Circulation 1995;5:1350.
Vesselinovitch D, Wissler RW, Fiseher-Dzoga K et al. Regression of atherosclerosis in rabbits. I. Treatment with low fat diet, hyperoxia and hypolipidemic agents. Atherosclerosis 1974;19:259.
Vincent GM, Anderson JL, Marshall HW. Coronary spasm producing coronary thrombosis and myocardial infarction. N Engl J Med 1983;309(14):220.
Vora NM, Williams GA, Hargis GK et al. Comparative effect of calcium and the adrenergic system on calcitonin secretion in man. J Clin Endocrinol Metab 1978; 46(4): 567.
Walker FMcG. The effects of EDTA chelation therapy on plaque calcium and mineral metabolism in atherosclerotic rabbits. Physiology (Dissertation Abstracts International) 1980;Vol. 41, No. 04.
Walker M. How to Prevent or Reverse Hardening of the Arteries in: Chelation Therapy. M Evans Co, Inc., New York, 1981.
Walker M. The Miracle Healing Power of Chelation Therapy. Canfield, Ohio, Fischer Publishing, 1984.
Walker M. The Chelation Way: The Complete Book of Chelation Therapy. Garden City Park, NY, Avery Publishing, 1990.
Walker M. Chelation Therapy: How to Prevent or Reverse Hardening of the Arteries. Atlanta, '76 Press, 1987.
Walker M, Gordon G. The chelation Answer. Atlanta, '76 Press, 1983.
Wartman A. Lampe TL, McCann DS et al. Plaque reversal with MgEDTA in experimental atherosclerosis: Elastin and collagen metabolism. J Atheros Res 1967;7: 331.
Weeden RP, Mallik DK, Batitman V. Detection and treatment of occupational lead nephropathy. Arch Intern Med. 1979;(139); 53.
Welcher FJ. The Analytical Uses of Ethylenediamine Tetraacetic Acid 5. Van Nostrand, Princeton.
What is chelation therapy for arteriosclerosis? Br Med J 1982; 285.
Whitaker, J. You have alternatives to bypass surgery. Health Healing Lett Feb, 1993.
Whitaker JA, Austin W, Nelson JD. Edathamil calcium disodium (Versenate) diagnostic test for lead poisoning. Pediatrics 1962;29:384.
Wilder LW, DeJode LR, Milstein SW, et al. Mobilization of atherosclerotic plaque calcium with EDTA utilizing the isolation-perfusion principle. Surgery 1962;52:793.
Willett WC, Morris JS, Pressel S, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983;2(8343):130.
Williams DR. An Introduction to Bio-inorganic Chemistry. Charles C. Thomas, Springfield, Illinois 1976.
Williams JD, Matthews GA, Judd AW. Oral calcium disodium versenate in treatment of lead poisoning. Brit J Indust Med 1962;19:211.
Wills ED. Mechanisms of lipid peroxide formation in tissues: Role of metals and haematin proteins in the catalysis of the oxidation of unsaturated fatty acids. Biochem Biophys Acta 1965;98:238.
Wirebaugh SR, Geraets DR. Apparent failure of edetic acid chelation therapy for the treatment of coronary atherosclerosis. DICP Ann Pharm 1990;24:22.
Wissler RW, Vesselinovitch D. Regression of atherosclerosis in experimental animals and man. Mod Concepts Cordiovasc Dis 1977;46:28.
Wynn JE, Riet B, Van T et al. The toxicity and pharmacodynamics of EGTA: oral administration to rats and comparisons with EDTA. Toxicol Appl Pharmacol 1970; 16:807.
Yang WC. Stimulatory effect of EDTA on cardiac mitochondrial respiration. Biochem Biophys Res Commun 1960;2:22.
Yokel RA. Hair as an indicator of excessive aluminum exposure. Clin Chem 1982;28(4): 662.
Rights and permissions
About this article
Cite this article
Rozema, T.C. The Protocol for the Safe and Effective Administration of EDTA and Other Chelating Agents for Vascular Disease, Degenerative Disease, and Metal Toxicity . Journal of Advancement in Medicine 10, 5–100 (1997). https://doi.org/10.1023/B:JAME.0000008701.26923.ab
Issue Date:
DOI: https://doi.org/10.1023/B:JAME.0000008701.26923.ab